Switching the System: A Novel Approach to Caring for Chronic Disease

Maisha Draves, MD, MPH Medical Director of Pharmacy The Permanente Medical Group

Nov. 8, 2022

KP Mission: Kaiser Permanente exists to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve.



The Permanente Medical Group




Disclosure

Maisha Draves, MD, MPH

- No Conflicts of Interest
- No financial disclosures
- No non-financial disclosures

Kaiser Permanente (KP) Facts




PERMANENTE MEDICINE®

The Permanente Medical Group

Pharmacy provides value as a frequent touchpoint

Kaiser Permanente Pharmacy

Our pharmacists and staff are often the last interaction and serve as a primary point of contact for members throughout the care delivery process







\$2.3 billion

in annual dispensing expenses⁴





Note: (1) Data is for outpatient claims only. (2) Inpatient internal claims based on MAR. (3) CAM internal claims only and may be lower than reality since not all clinic meds are documented correctly via MAR. Source: (4) Total KP Pharmacy Drug Expense and Dispensing Costs 2020 (National Pharmacy Finance); (5) KP Pharmacy Facilities Count (with KP Washington); (6) KP pharmacy Employee Counts - PeopleSoft as of 4/30/2021 = 13,849; (7) Total KP Pharmacy average daily number of members receiving medication [outpatient, inpatient, oncology/infusion], 2020. **Learning Objectives**

•Understand what a Biosimilar is

 Kaiser Permanente internal Academic Detailing to physicians, pharmacists, nurses and patient education

•Kaiser Permanente Uptake of Biosimilars vs USA


PERMANENTE MEDICINE.

Biologics and Biosimilars


CONFIDENTIAL AND PROPRIETARY: FOR INTERNAL KAISER USE ONLY

- Biologics: Medications made from living cells through highly complex manufacturing processes
- Biosimilars are:
 - Highly similar to the reference product notwithstanding minor differences in clinically inactive components and
 - Have no clinically meaningful differences compared with the reference product in terms of safety, purity, and potency

	Traditional Drugs	Biologics
Source	Pure chemical substances	Living organisms
Structure	Simple, small-molecules; easy to identify and characterize	Complex, large-molecules; harder to identify or characterize
Manufacturing	Synthesized via predictable chemical process	Complicated biotechnology or other cutting-edge method; some batch-to-batch variation expected
Reproducibility	Can be exactly reproduced	Cannot be exactly reproduced, due to natural variation
	(Generics are chemically identical)	(Biosimilars are highly similar)
	Additional	



Do you incorporate academic detailing on biosimilars to physicians, pharmacists, or nurses?



Start the presentation to see live content. For screen share software, share the entire screen. Get help at pollev.com/app



Kaiser Permanente's Approach

Integrated, Evidence based Model to Drive Quality, Safety and Affordability

Why Move to Biosimilars?


- Biosimilars offer equivalent efficacy and safety to originator products, often at a reduced cost
- Similar to generics introduction to the market
 - Initially concerns about generics efficacy/safety
 - Many years to develop acceptance of generics
 - Generics and biosimilars are a key component of maintaining high quality, affordable, and accessible care for our members
 - Benefits of Biosimilars

Drive biologic price competition	Increase treatment options
 Discount from reference product WAC: Zarxio (filgrastim-sndz): 15% Inflectra (infliximab-dyyb): 15% Renflexis (infliximab-abda): 35% 	 Offers equally safe & effective alternatives at a lower cost Expands patient access to biologics Allows payors to direct resources to other medicines or healthcare needs
WAC = Wholesale Acquisition Cost	


"Industry analysts say that biosimilars are on track to reduce U.S. drug expenditure by \$133 billion by 2025."

https://www.cardinalhealth.com/content/dam/corp/web/documents/Report/c ardinal-health-2022-biosimilars-report.pdf

Kaiser Permanente Biosimilar Journey




Kaiser Permanente Process for Biosimilars



KP's has the **ability to move market share**. Our actual purchase volume relative to chains or GPOs is quite small. The leverage exists because:

- •KP can promise and deliver greater than 90% of a given market in a very short period of time
- KP's 12.4M members represent about 4% of covered lives in the U.S.

Education Remains a Pivotal Factor




Ongoing conversations and development of materials discussing **biosimilar experiences**

External input (US and EU) on biosimilars has enhanced conversations within KP

Dedication to pharmacovigilance efforts

Samples of Documents and Tools



For Providers

- Flyers, Posters, FAQs
- Presentation Slides
- Pocket Guides
- Talking Points
- Newsletter Articles
- Utilization Data


For Members

- Patient Letters
- Patient Handouts
- Exam Room Posters
- Newsletter Articles



Copyright © 2021 Kaiser Foundation Health Plan, Inc.

Communication & Education





Copyright © 2021 Kaiser Foundation Health Plan, Inc.

Academic Detailing of Physicians

Focus Areas Implementing Biosimilars

Efficacy	Safety	Immunogenicity	Indications (extrapolation)
Treatment category	Treatment intent	New vs existing patients	Infusion time
Patient copay	Reimbursement rates	Staff education	Patient education
Patent litigations	Supply & stocking	Clinical trial use	Formulation presentation
	Evergreening	Administrative Issues	

Academic Detailing of Nursing, Infusion Staff

Patient Communication

Focus Areas Implementing Biosimilars

Efficacy	Safety	Immunogenicity	Indications
Treatment category	Treatment intent	New vs existing patients	Infusion time
Patient copay	Reimbursement rates	Staff education	Patient education
Patent litigations	Supply & stocking	Clinical trial use	Formulation presentation
	Evergreening	Administrative Issues	

Academic Detailing of Pharmacy and Administration

Focus Areas Implementing Biosimilars

Efficacy	Safety	Immunogenicity	Indications
Treatment category	Treatment intent	New vs existing patients	Infusion time
Patient copay	Reimbursement rates	Staff education	Patient education
Patent litigations	Supply & stocking	Clinical trial use	Formulation presentation
	Evergreening	Administrative Issues	

KP Real-World-Evidence on Biosimilars




 Retrospective real-world studies at KP on biosimilars have not shown any safety or efficacy concerns


	Abstract #096	Platform Category A2	
	Effectiveness and safety of trastuzu compared to reference product	mab-anns	Filgrastim-sndz (Zarxio) vs Filgrastim (Neupogen) in Preventing Febrile Neutropenia
	Dara D. Nguyen, PharmD, BCPS PGY2 Medication Use Safety & Policy Resident	ABSTRACTS & PRESENTATIONS	NCAL Drug Use Management - CAMs Are 21 222 Contrave Favorationistic Provided and ex. Kasser PERMANENTE
BioDrugs https://doi.org/10.1007/s40259-020-00409-y	Drug Intelligence and Strategy Kaiser Permanente	2022 ASCO Annual Meeting - Poste	er Session
ORIGINAL RESEARCH ARTICLE		Real-world outcomes of bios	imilar bevacizumab-awwb versus reference
	IRB Accepted	bevacizumab in patients with	n metastatic colorectal cancer.
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study		Bevacizumab-awwb was the first biosimilar approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer and became available for use in July 2019. Clinical comparative efficacy and safety of bevacizumab-awwb to bevacizumab was established in a single study of Abstract: 3552 Poster Bd #: 346	
Study Stephanie L. Ho ¹ · Fang Niu ² · Suresh Pola ³ · Fer	nando S. Velayos⁴ · Xian Ning¹ · Rita L. Hui⁵©	Catherine Pham PharmD	
01	NTIAL INFORMATION – internal use only. Do not disclose ext		

Evidence of increased utilization of biosimilars in the US: avg 33-74% uptake

Biosimilars Share of Total Units by Drug Class 2018 compared to 12 months ending March 2021



Kaiser Permanente Experience with Biosimilars avg 88 to 99% uptake



93 1. (14) Chau J, et al. ACR Open Rheumatol, 2019; (16) Awsare S, et al. Health Affairs Blog, 2019; (28) Gutierrez A. GRx+Biosims Conference, 2019

Much appreciation to our patients, and the many members of our talented physician and pharmacist teams that drive biosimilar use every day

Thank you!

PERMANENTE MEDICINE®